

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Avner YAYON *et al.*

Application No.:

Group Art Unit:

Filing Date: Concurrently herewith

Examiner:

For: ANTIBODIES THAT BLOCK RECEPTOR
PROTEIN TYROSINE KINASE ACTIVATION

Attorney Docket No.: 81408-4400

INFORMATION DISCLOSURE STATEMENT

Mail Stop Patent Application

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Pursuant to applicants' duty of disclosure under 37 C.F.R. § 1.56, enclosed is a Form PTO-1449 containing eighty-one (81) references for the Examiner's review and consideration. Copies of references B1-B15 and C1-38 are also enclosed. Copies of references A1-A28 will be provided if the Examiner so requests.


It is respectfully requested that the references be made of record in this application by the Examiner's completion and return of the enclosed Form PTO-1449.

This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(b) before the latter of three months after the U.S. patent application filing date or the first Office Action on the merits. Accordingly, no fee or certification is required. Should any fees be required, however, please charge such fees to Winston & Strawn LLP Deposit Account No. 50-1814.

Respectfully submitted,

12/15/03

Date



Rodney J. Fuller (Reg. No. 46,714)
For: Allan A. Fanucci (Reg. No. 30,256)

WINSTON & STRAWN LLP
Customer No. 28765

202-371-5838

| | | |
|--|---------------------------------------|------------------|
| LIST OF REFERENCES CITED BY APPLICANT Form PTO-1449 <i>(Use several sheets if necessary)</i> | ATTY. DOCKET NO.: 81408-4400 | APPLICATION NO.: |
| | APPLICANT: Avner YAYON, et al. | |
| Sheet 1 of 4 | FILING DATE: Concurrently herewith | GROUP: |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----------|-----------------|---------|-------------------|-------|----------|----------------------------|
| *EXAMINER INITIAL | CITE NO. | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | A1 | 4,376,110 | 03/1983 | David et al. | 435 | 5 | |
| | A2 | 4,816,567 | 03/1989 | Cabilly et al. | 530 | 387.3 | |
| | A3 | 4,946,778 | 08/1990 | Ladner et al. | 435 | 69.6 | |
| | A4 | 4,966,849 | 10/1990 | Vallee et al. | 435 | 199 | |
| | A5 | 5,091,513 | 02/1992 | Huston et al. | 530 | 387.3 | |
| | A6 | 5,096,815 | 03/1992 | Ladner et al. | 435 | 69.1 | |
| | A7 | 5,225,539 | 07/1993 | Winter | 530 | 387.3 | |
| | A8 | 5,330,992 | 07/1994 | Eissenstat et al. | 514 | 312 | |
| | A9 | 5,459,015 | 10/1995 | Janjic et al. | 435 | 6 | |
| | A10 | 5,530,101 | 06/1996 | Queen et al. | 530 | 387.3 | |
| | A11 | 5,585,089 | 12/1996 | Queen et al. | 424 | 133.1 | |
| | A12 | 5,677,171 | 10/1997 | Hudziak et al. | 435 | 7.23 | |
| | A13 | 5,693,761 | 12/1997 | Queen et al. | 536 | 23.53 | |
| | A14 | 5,693,762 | 12/1997 | Queen et al. | 530 | 387.3 | |
| | A15 | 5,707,632 | 01/1998 | Williams et al. | 424 | 198.1 | |
| | A16 | 5,772,997 | 06/1998 | Hudziak et al. | 424 | 130.1 | |
| | A17 | 5,840,301 | 11/1998 | Rockwell et al. | 424 | 143.1 | |
| | A18 | 5,910,573 | 06/1999 | Pluckthun et al. | 530 | 387.3 | |
| | A19 | 5,942,602 | 08/1999 | Wels et al. | 530 | 388.22 | |
| | A20 | 6,129,915 | 10/2000 | Wels et al. | 424 | 143.1 | |
| | A21 | 6,165,464 | 12/2000 | Hudziak et al. | 424 | 142.1 | |
| | A22 | 6,183,975 | 02/2001 | Gargus et al. | 435 | 7.21 | |
| | A23 | 6,214,974 | 04/2001 | Rosenblum et al. | 530 | 391.9 | |
| | A24 | 6,294,353 | 09/2001 | Pack et al. | 435 | 69.1 | |
| | A25 | 6,300,064 | 10/2001 | Knappik et al. | 435 | 6 | |
| | A26 | 6,342,219 | 01/2002 | Thorpe et al. | 424 | 145.1 | |
| | A27 | 6,365,157 | 04/2002 | Rockwell et al. | 424 | 156.1 | |
| | A28 | 6,399,063 | 06/2002 | Hudziak et al. | 424 | 138.1 | |

| | |
|---|-----------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | |
|--|---------------------------------------|------------------|
| LIST OF REFERENCES CITED BY APPLICANT Form PTO-1449 <i>(Use several sheets if necessary)</i> | ATTY. DOCKET NO.: 81408-4400 | APPLICATION NO.: |
| | APPLICANT: Avner YAYON, et al. | |
| Sheet 2 of 4 | FILING DATE: Concurrently herewith | GROUP: |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-----|-----------------|------|---------|-------|----------|-------------|----|
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | YES | NO |
| | B1 | 0 125 023 | | EPO | | | | |
| | B2 | 0 171 496 | | EPO | | | | |
| | B3 | 0 173 494 | | EPO | | | | |
| | B4 | 0 184 187 | | EPO | | | | |
| | B5 | WO 86/01533 | | WIPO | | | | |
| | B6 | WO 87/02671 | | WIPO | | | | |
| | B7 | WO 90/07861 | | WIPO | | | | |
| | B8 | WO 92/22653 | | WIPO | | | | |
| | B9 | WO 93/15210 | | WIPO | | | | |
| | B10 | WO 94/10202 | | WIPO | | | | |
| | B11 | WO 94/14808 | | WIPO | | | | |
| | B12 | WO 96/13583 | | WIPO | | | | |
| | B13 | WO 96/37621 | | WIPO | | | | |
| | B14 | WO 97/08320 | | WIPO | | | | |
| | B15 | WO 00/68424 | | WIPO | | | | |
| | | | | | | | | |

| OTHER REFERENCES <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i> | |
|--|---|
| C1 | Baselga and Albanell, Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol. 12 Suppl 1:S35-41 (2001) |
| C2 | Bellus et al., Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes. Nature Genetics, 14:174-76 (1996) |
| C3 | Better et al, ", Escherichia coli secretion of an active chimeric antibody fragment. Science 240(4855):1041-43 (1988) |
| C4 | Billerey, et al., Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 158(6):1955-9 (2001) |
| C5 | Blume-Jensen and Hunter, Oncogenic kinase signalling. Nature 411:355-65 (2001) |
| C6 | Boulianne et al, Production of functional chimaeric mouse/human antibody. Nature 312(5995):643-646 (1984) |
| C7 | Cabilly, et al., Generation of antibody activity from immunoglobulin polypeptide chains produced in Escherichia coli. PNAS U S A, 81(11):3273-7 (1984) |

| | |
|--|------------------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | |
|--|---------------------------------------|------------------|
| LIST OF REFERENCES CITED BY APPLICANT Form PTO-1449 <i>(Use several sheets if necessary)</i> | ATTY. DOCKET NO.: 81408-4400 | APPLICATION NO.: |
| Sheet 3 of 4 | APPLICANT: Avner YAYON, et al. | |
| | FILING DATE: Concurrently herewith | GROUP: |

| OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|---|--|--|
| C8 | Cappellen et al., Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. <i>Nature Genetics</i> , 23:18-20 (1999) | |
| C9 | Chesi et al., Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. <i>Blood</i> , 97(3):729-736 (2001) | |
| C10 | Frank, Growth factors in age-related macular degeneration: pathogenic and therapeutic implications. <i>Ophthalmic Res</i> 29:341-53 (1997) | |
| C11 | Galvin et al., Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR)2 and FGFR2/Neu chimeras. <i>PNAS USA</i> , 93:7894-99 (1996) | |
| C12 | Gerwins et al., Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. <i>Crit Rev Oncol Hematol</i> 34(3):185-94 (2000) | |
| C13 | Grigoriadis et al, Differentiation of muscle, fat, cartilage, and bone from progenitor cells present in a bone-derived clonal cell population: effect of dexamethasone. <i>J Cell Biol</i> 106(6):2139-51 (1988) | |
| C14 | Knappik et al., Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. <i>J. Mol. Biol.</i> , 296:57-86 (2000) | |
| C15 | Kohfeldt et al., Properties of the extracellular calcium binding module of the proteoglycan testican. <i>FEBS Lett.</i> 414:557-561, 1997 | |
| C16 | Kohler and Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity. <i>Nature</i> , 256(5517):495-497 (1975) | |
| C17 | Liu et al, Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. <i>PNAS USA</i> . 84(10):3439-3443 (1987) | |
| C18 | Meinkoth and Wahl, Hybridization of nucleic acids immobilized on solid supports., <i>Anal Biochem</i> 138:267-284 (1984) | |
| C19 | Meyers et al., Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. <i>Nature Genetics</i> , 11:462-464 (1995) | |
| C20 | Morrison et al., Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. <i>PNAS USA</i> 81(21):6851-6855 (1984) | |
| C21 | Muenke et al., A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. <i>Am. J. Hum. Genet.</i> , 60:555-64 (1997) | |
| C22 | Neuberger et al, A hapten-specific chimaeric IgE antibody with human physiological effector function. <i>Nature</i> 314(6008):268-270 (1985) | |
| C23 | Ornitz, Regulation of chondrocyte growth and differentiation by fibroblast growth factor receptor 3. <i>Novartis Found Symp</i> 232:63-76; discussion 76-80, 272-82 (2001) | |
| C24 | Ornitz and Itoh, Fibroblast Growth Factors, <i>Genome Biol</i> 2(3):review 3005.1-3005.12 (2001) | |
| C25 | Plowright et al., Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. <i>Blood</i> 95(3):992-8 (2000) | |
| C26 | Ronchetti, et al., Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. <i>Oncogene</i> 20(27):3553-62 (2001) | |

| | |
|---|------------------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | |
|--|---------------------------------------|------------------|
| LIST OF REFERENCES CITED BY APPLICANT Form PTO-1449 <i>(Use several sheets if necessary)</i> | ATTY. DOCKET NO.: 81408-4400 | APPLICATION NO.: |
| | APPLICANT: Avner YAYON, et al. | |
| Sheet 4 of 4 | FILING DATE: Concurrently herewith | GROUP: |

| OTHER REFERENCES <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i> | | |
|--|-----|---|
| | C27 | Sahagan, et al., A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen. J Immunol. 137(3):1066-74 (1986) |
| | C28 | Sahni, et al., FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 13(11):1361-6 (1999) |
| | C29 | Saito et al., Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol, 21(19):6387-94 (2001) |
| | C30 | Sato et al., Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction. Ann N Y Acad Sci, 902:201-5; discussion 205-7 (2000) |
| | C31 | Saltzman and Langer, Transport rates of proteins in porous materials with known microgeometry. Biophys. J, 55:163 (1989) |
| | C32 | Schell et al., Mutations in FGFR1 and FGFR2 cause familial and sporadic Pfeiffer syndrome. Hum Mol Gen, 4:323-328 (1995) |
| | C33 | Sherwood et al., Controlled antibody delivery systems. Biotechnology, 10(11):1446-9 (1992) |
| | C34 | Tavormina et al., A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am. J. Hum. Genet., 64:722-31 (1999) |
| | C35 | Vajo et al., The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocrine Reviews, 21(1):23-39 (2000) |
| | C36 | van Rhijn et al., Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol. 21(10):1912-21 (2003) |
| | C37 | Webster and Donoghue, FGFR activation in skeletal disorders: too much of a good thing. Trends Genetics 13(5):178-82 (1997) |
| | C38 | Yamaguchi et al., Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 18(16):4414-23 (1999) |

| | |
|---|-----------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |